Titan Pharmaceuticals (NASDAQ:TTNP) Downgraded by Maxim Group to Hold

Maxim Group lowered shares of Titan Pharmaceuticals (NASDAQ:TTNPGet Rating) to a hold rating in a report released on Thursday morning, Stock Target Advisor reports.

Separately, StockNews.com initiated coverage on shares of Titan Pharmaceuticals in a research report on Saturday, May 21st. They set a hold rating for the company.

Shares of Titan Pharmaceuticals stock opened at $0.40 on Thursday. The company has a fifty day moving average price of $0.74 and a 200 day moving average price of $1.01. Titan Pharmaceuticals has a twelve month low of $0.35 and a twelve month high of $3.10.

A hedge fund recently raised its stake in Titan Pharmaceuticals stock. Morgan Stanley raised its position in Titan Pharmaceuticals, Inc. (NASDAQ:TTNPGet Rating) by 1,058,500.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 158,790 shares of the specialty pharmaceutical company’s stock after buying an additional 158,775 shares during the period. Morgan Stanley owned approximately 1.61% of Titan Pharmaceuticals worth $413,000 at the end of the most recent quarter. 18.86% of the stock is owned by institutional investors and hedge funds.

About Titan Pharmaceuticals (Get Rating)

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union.

Further Reading

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.